Colorado-based Enveda, which uses AI to discover new drugs in the natural world, raised a $311M Series E at a $2B valuation, double its valuation a year ago (Marina Temkin/TechCrunch)

Enveda’s $311M Series E at a $2B valuation underscores continued investor confidence in AI-driven drug discovery and the growing commercial potential of applying advanced models to high-value scientific problems. For CIOs and technology leaders, this signals that competitive advantage is increasingly tied to robust AI, data, and cloud infrastructure capable of accelerating R&D, improving decision-making, and scaling proprietary model development in regulated environments.